At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Tofacitinib Hypothesis-generating, Pilot Study for Corticosteroid-Dependent Sarcoidosis
In Brief
A Phase 1 clinical trial evaluating Tofacitinib 5mg Oral Tablet [Xeljanz] 16 week trial, Spirometry, and 4 other interventions for Sarcoidosis, Pulmonary and 2 related conditions. Completed, enrolled 5 participants across 1 site.
Detailed Summary
This is a pilot study to determine whether further research is warranted to assess whether tofacitinib is an effective steroid sparing treatment for pulmonary sarcoidosis. The primary endpoint for this study is a 50% or greater reduction in corticosteroid requirement.
Study Details
Timeline
Interventions
Tofacitinib 5mg oral table twice daily for 16 weeks
Spirometry testing at baseline, week 4, week 8, week 12, and week 16
RNA sequencing test at baseline and week 16
Laboratory testing at baseline and weeks 2, 4, 8, 12 and 16
Taper corticosteroids starting at week 4
After 16 weeks, subjects who meet the primary end-point will be permitted an optional one year open-label extension.